Univ of Michigan
Welcome,         Profile    Billing    Logout  
 6 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Phillips, Tycel
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
NCT03921879: Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Recruiting
1
50
US
OT-82 Dose Escalation, OT-82 Dose Expansion
Oncotartis, Inc.
Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Follicular, Lymphoma, Peripheral T-Cell, Lymphoma, Hodgkin
04/21
06/21
XmAb13676-01, NCT02924402: Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Checkmark Presentation of data from trial for NHL at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from trial for NHL at ASH 2022
Checkmark From trial for NHL and CLL at ASH 2021
Dec 2021 - Dec 2021: From trial for NHL and CLL at ASH 2021
Checkmark From trial in hematologic malignancies at ASH 2019
More
Completed
1
154
Europe, US, RoW
XmAb13676
Xencor, Inc., ICON Clinical Research
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
04/24
04/24
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
NCT04431635: Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Terminated
1
6
US
Copanlisib, Nivolumab, Rituximab
University of Michigan Rogel Cancer Center, Bayer, Bristol-Myers Squibb, University of Michigan, Big Ten Cancer Research Consortium
Indolent Lymphoma
11/23
11/23
Answerline, U-M Cancer
No trials found

Download Options